- $24.59bn
- $21.44bn
- $8.26m
Roivant Sciences Ltd reports results for the quarter ended in June - Earnings Summary
Brief: Roivant Sciences Q1 Adjusted Net Income USD 57.49 Million Vs. IBES Estimate USD -208.4 Million
Roivant Sciences Ltd expected to post a loss of 26 cents a share - Earnings Preview
BuzzFeed jumps as Vivek Ramaswamy reports stake boost
Roivant Sciences Ltd reports results for the quarter ended in March - Earnings Summary
Brief: Roivant Sciences Q4 Net Income USD -182.496 Million
Roivant Sciences Ltd expected to post a loss of 30 cents a share - Earnings Preview
BuzzFeed surges as Vivek Ramaswamy reveals stake
Brief: Roivant And Kinevant Sciences Complete Enrollment In RESOLVE-Lung, A Phase 2 Study Evaluating Namilumab
Moderna shares fall after judge sides with Arbutus in patent fight (updated)
Moderna slides after judge sides with Arbutus in patent fight
Moderna shares fall after judge sides with Arbutus in patent fight
U.S. STOCKS ON THE MOVE-Paychex, ChampionX, EV stocks
U.S. STOCKS ON THE MOVE-VirTra, GE Vernova, Blackstone
U.S. STOCKS ON THE MOVE-PVH, Verve Therapeutics, Canoo
Roivant jumps after anti-inflammatory drug succeeds in mid-stage study
Roivant's anti-inflammatory drug succeeds in mid-stage study (updated)
To Book About 55 Billion Yen Gain On Sale Of Roivant Sciences Shares In Parent-Only Q1 FY2025 Earnings
Roivant's anti-inflammatory drug succeeds in mid-stage study